MedTrace Logo

Vitamin D Supplementation in HIV Youth

NCT01523496 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2018-03-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the correct dose of Vitamin D to give to prevent HIV related complications.

Conditions

  • HIV Infections

Interventions

DRUG

Vitamin D control dose

18,000 IU per month

DRUG

Vitamin D supplementation-

60,000 IU per month(medium dose) or 120,000 IU/month(high dose)

Sponsors & Collaborators

  • Emory University

    collaborator OTHER

  • University Hospitals Cleveland Medical Center

    lead OTHER

Principal Investigators

  • Grace McComsey, MD, FIDSA · University Hospitals Cleveland Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01523496 on ClinicalTrials.gov